|Bid||23.25 x 800|
|Ask||23.73 x 800|
|Day's Range||23.43 - 24.23|
|52 Week Range||13.67 - 27.80|
|Beta (5Y Monthly)||1.20|
|PE Ratio (TTM)||49.53|
|Earnings Date||Feb 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.83|
Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.
Exelixis, Inc. (Nasdaq: EXEL) today announced its preliminary unaudited financial results for the fourth quarter and full year 2020, provided financial guidance for full year 2021, and delivered an update on its business. This 2021 financial guidance takes into consideration the anticipated U.S. Food and Drug Administration (FDA) approval and commercial launch of CABOMETYX® (cabozantinib) in combination with OPDIVO® (nivolumab) as a first-line treatment for patients with advanced renal cell carcinoma (RCC), which has a Prescription Drug Use Fee Act (PDUFA) target action date of February 20, 2021.
If you want sizzling returns, look no further than the biotech industry. The SPDR S&P Biotech ETF (NYSEMKT: XBI) -- a pretty good barometer for biotechs -- delivered a 48% gain last year. That marked the best performance for the ETF since 2013, when it soared by roughly the same amount.